**FOI Ref: 6038**

**Category(ies): Clinical - Drugs**

**Subject: The usage of anti-VEGF treatments for eye conditions**

**Date Received: 28/09/21**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatements:* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Fluocinolone acetonide
* Ranibizumab
 | 3140471327483 |
| 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Fluocinolone acetonide
* Ranibizumab
 | 7030015 |
| 3. Within your trust, how many intra-vitreal injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Ranibizumab
 | 705091131054 |
| 4. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY* Aflibercept
* Bevacizumab
* Brolucizumab
* Dexamethasone
* Ranibizumab
 | 3680910571 |